Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;18(3):220144.
doi: 10.1183/20734735.0144-2022. Epub 2022 Nov 15.

Quality standards for managing children and adolescents with bronchiectasis: an international consensus

Anne B Chang  1   2   3 , Jeanette Boyd  4 , Andrew Bush  5   6 , Adam T Hill  7   8 , Zena Powell  9 , Angela Zacharasiewicz  10 , Efthymia Alexopoulou  11 , James D Chalmers  12   13 , Andrew J Collaro  1   2 , Carolina Constant  14 , Konstantinos Douros  15 , Rebecca Fortescue  16 , Matthias Griese  17 , Jonathan Grigg  18 , Andreas Hector  19   20 , Bulent Karadag  21 , Oleksandr Mazulov  22   23 , Fabio Midulla  24 , Alexander Moeller  19   20 , Marijke Proesmans  25 , Christine Wilson  26 , Stephanie T Yerkovich  1   2   3 , Ahmad Kantar  27   28 , Keith Grimwood  29   30   28
Affiliations
Review

Quality standards for managing children and adolescents with bronchiectasis: an international consensus

Anne B Chang et al. Breathe (Sheff). 2022 Sep.

Abstract

The global burden of bronchiectasis in children and adolescents is being recognised increasingly. However, marked inequity exists between, and within, settings and countries for resources and standards of care afforded to children and adolescents with bronchiectasis compared with those with other chronic lung diseases. The European Respiratory Society (ERS) clinical practice guideline for the management of bronchiectasis in children and adolescents was published recently. Here we present an international consensus of quality standards of care for children and adolescents with bronchiectasis based upon this guideline. The panel used a standardised approach that included a Delphi process with 201 respondents from the parents and patients' survey, and 299 physicians (across 54 countries) who care for children and adolescents with bronchiectasis. The seven quality standards of care statements developed by the panel address the current absence of quality standards for clinical care related to paediatric bronchiectasis. These internationally derived, clinician-, parent- and patient-informed, consensus-based quality standards statements can be used by parents and patients to access and advocate for quality care for their children and themselves, respectively. They can also be used by healthcare professionals to advocate for their patients, and by health services as a monitoring tool, to help optimise health outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: E. Alexopoulou, A. Bush, C. Constant, K. Douros, R. Fortescue, M. Griese, A. Hector, B. Karadag, A.T. Hill, A. Kantar, O. Mazulov, F. Midulla, A. Moeller, M. Proesmans, S.T. Yerkovich, A. Zacharasiewicz, Z. Powell, C. Wilson and A.J. Collaro have nothing to disclose. J. Boyd is an employee of the European Lung Foundation. A.B. Chang reports grants from National Health and Medical Research Council, Australia, during the conduct of the study; monies provided to institution from IDMC Membership of unlicensed products (GSK, AstraZeneca), and vaccine (Moderna), other from Advisory member of study design for unlicensed molecules for chronic cough or bronchiectasis (Merck, Zambon, Boehringer Ingelheim); personal fees from being an author of two UpToDate chapters, outside the submitted work. J.D. Chalmers reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, personal fees from Chiesi, grants and personal fees from GlaxoSmithKline, grants from Gilead Sciences, grants and personal fees from Insmed, personal fees from Novartis, personal fees from Zambon, outside the submitted work. J. Grigg reports grants and personal fees from OM Pharma, personal fees from GSK, personal fees from Novartis, personal fees from Omron, personal fees from Astra Zeneca, outside the submitted work. K. Grimwood reports grants from Australian National Health and Medical Research Council and the Australian Medical Research Future Fund during the conduct of the study.

Figures

FIGURE 1
FIGURE 1
Comparison of the weighted average for each of the quality standard (QS) of care statements from both surveys. Rating scale: 1 (strongly agree) to 5 (strongly disagree). HCP: healthcare professional.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. Lancet 2018; 392: 866–879. doi:10.1016/S0140-6736(18)31554-X - DOI - PubMed
    1. Chalmers JD, Chang AB, Chotirmall SH, et al. . Bronchiectasis. Nature Rev Dis Primers 2018; 4: 45. doi:10.1038/s41572-018-0042-3 - DOI - PubMed
    1. McCallum GB, Chang AB. ‘Good enough' is ‘not enough' when managing Indigenous adults with bronchiectasis in Australia and New Zealand. Respirology 2018; 23: 725–726. doi:10.1111/resp.13291 - DOI - PubMed
    1. Goyal V, Grimwood K, Masters IB, et al. . Pediatric bronchiectasis: no longer an orphan disease. Pediatr Pulmonol 2016; 51: 450–469. doi:10.1002/ppul.23380 - DOI - PubMed
    1. Polverino E, Cacheris W, Spencer C, et al. . Global burden of non-cystic fibrosis bronchiectasis: a simple epidemiological analysis. Eur Respir J 2012; 40: Suppl. 56, P3983.

LinkOut - more resources